“滋燥养荣汤”治疗表皮生长因子受体抑制剂相关皮肤干燥的回顾性研究  

Retrospective study on the treatment of EGFR inhibitor-related skin dryness in non-small cell lung cancer patients with"Zizao Yangrong Decoction"

作　　者：沈雨蕾 翟烨 郑玉敏 吴带喜 刘哲宁 张晓佳 董慧静 王奥林 李嘉 崔慧娟[2] SHEN Yu-lei;ZHAI Ye;ZHENG Yu-min(Beijing University of Chinese Medicine,Beijing 100029,China)

机构地区：[1]北京中医药大学,北京100029 [2]中日友好医院中西医结合肿瘤内科,北京100029 [3]北京中医药大学东直门医院皮肤科,北京100700

出　　处：《中日友好医院学报》2025年第1期7-12,共6页Journal of China-Japan Friendship Hospital

基　　金：中日友好医院临床研究与转化跃升项目(2022-NHL-HCRF-LX-02-0111);国家重点研发计划中医药现代化项目(2018YFC1705101)。

摘　　要：目的:评估院内协定处方“滋燥养荣汤”治疗表皮生长因子受体抑制剂(EGFRIs)相关皮肤干燥的有效性和安全性。方法:回顾性收集2020年1月—2023年6月间于我院应用“滋燥养荣汤”治疗EGFRIs相关皮肤干燥的非小细胞肺癌患者的资料,依据服用剂量分为高暴露组和低暴露组,对患者的症状改善情况、生存情况以及服药物相关不良事件进行电话随访,比较2组患者的疗效和安全性。结果:纳入53例患者,将“滋燥养荣汤”连续服用剂数的中位数28作为截断值,分为高暴露组21例、低暴露组32例。至随访截点,治疗总有效率为84.9%,高暴露组和低暴露组的有效率分别是81.0%和87.5%,皮肤干燥的分级、部位及部位计数均较治疗前改善,伴随瘙痒及手足皲裂症状也较前减轻,生活质量评分均较治疗前升高,差异均有统计学意义(P<0.05)。整体的中位无进展生存期为45.63个月,高暴露组和低暴露组分别为45.63个月和41.07个月,2组间差异无统计学意义(P>0.05)。患者中2例(3.7%)出现2级腹泻,分析原因与滋燥养荣汤治疗无关,无其它不良反应。结论:“滋燥养荣汤”治疗EGFRIs相关皮肤干燥具有良好的疗效及安全性,且在防治靶向药不良反应减毒同时不影响疗效。Objective:To evaluate the efficacy and safety of the hospital-formulated prescription"Zizao Yangrong Decoction"in treating epidermal growth factor receptor inhibitors(EGFRIs)-related skin dryness in patients with non-small cell lung cancer(NSCLC).Methods:A retrospective data from patients treated with"Zizao Yangrong Decoction"for EGFRIs-related skin dryness was conducted between January 2020 and June 2023.Based on the dosage administered,patients were categorized into high-exposure and low-exposure groups.The telephone follow-ups were conducted to assess the improvement of symptoms,survival status,and drug-related adverse events.Results:A total of 53 patients with NSCLC were included in the study.With a median of 28 doses of"Zizao Yangrong Decoction"as the cutoff value,the patients were divided into a highexposure group(n=21)and a low-exposure group(n=32).At the follow-up point,the overall effective rate of treatment was 84.9%,with effective rates of 81.0% and 87.5% in the high-exposure and low-exposure groups,respectively.The grading,location,and count of skin dryness showed significant improvement,while symptoms of itching and hand-foot fissures were also alleviated.Quality of life scores increased compared to pre-treatment,with all statistically significant differences(P<0.05).No significant differences were observed between the median progression-free survival(mPFS)of the two groups(45.63 vs 41.07months).Two(3.7%)patients experienced grade 2 diarrhea unrelated to the treatment with"Zizao Yangrong Decoction",and no other adverse reactions occurred.Conclusion:The"Zizao Yangrong Decoction"demonstrates a favorable efficacy and safety profile in the treatment of skin dryness associated with EGFRIs.Furthermore,it effectively mitigates the adverse reactions of targeted therapies without compromising their therapeutic efficacy.

关 键 词：非小细胞肺癌 表皮生长因子受体抑制剂 滋燥养荣汤 皮肤干燥 疗效 

分 类 号：R273[医药卫生—中西医结合]